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The Royal Marsden NHS Foundation Trust, The GI Unit, London, United Kingdom
Toxicity is an inevitable consequence of cancer treatment. While patients want curative treatment if possible, quality of life issues have been somewhat neglected in the race to improve survival.
Patient reported outcome measures (PROMS) confirm that most routinely used clinical scoring systems fail to identify important toxicities and as a result the frequency, severity and impact on patients' lives of chronic GI consequences of cancer therapies has historically not been fully recognised by clinicians. Nor has it received the attention that it deserves in terms of research. Yet the iatrogenically driven morbidity of cancer treatments and especially radiotherapy is an important human model of GI disease and has already yielded new insights which can be applied to benign and malignant diseases. In the last 20 years, a largely unheralded but spectacular revolution in understanding why toxicity develops, how it should be identified, measured and managed has gathered speed. Inaccurate terminology describing toxicity in the past has significantly hindered progress. It is now recognised that toxicities rarely affect just one organ system and the concept that toxicities after radical treatment are a progressive disease, Pelvic Radiation Disease, have helped formulate more productive treatment approaches and understand future priorities. Clinical studies now show that applying this new understanding allows much GI toxicity previously widely regarded as incurable to be ameliorated. In addition, biomarkers of radiation toxicity -fibrotic markers which can be measured in blood are the most promisingoffer a much more accurate method of detecting toxicity than the current approach of defining toxicity by a change in symptoms and this is starting to allow new methods of preventing toxicity, to be targeted more accurately.
It is also increasingly understood that the "consequential effect" has a critical role in the development of chronic toxicity and that it is driven by factors beyond the control of the oncologist. One of the most important of these is the composition of the gut microbiota; another is the role of the immune system. Introducing techniques already used by other disciplines to manipulate these factors will deliver future great rewards in terms of reducing chronic toxicity. GI toxicity is a major limiting factor to the advance of oncological treatments. Many new solutions have emerged but require the harnessing of a multidisciplinary approach in a way that oncology has rarely used up to this point.
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Intestinal radiation injury may severely hamper quality of life during and after treatment of abdominal tumors. Even though novel technical advances in treatment delivery have enabled more selective irradiation of the tumor, normal tissue radiation injury remains the most important dose limiting factor of radiotherapy. Hence, there is an urgent need for agents that can be administered during radiotherapy to prevent and/or reduce radiation-induced intestinal injury. These agents should of course not hamper the anti-tumor effect of radiation and, ideally, even improve radiationinduced tumor cell kill. Pre-clinical studies have shown that the novel Somatostatin analogue Pasireotide effectively reduces radiation-induced intestinal injury by preventing post-irradiation pancreatic enzyme-dependent intestinal auto-digestion. In our experiments Pasireotide was shown to preserve the intestinal mucosal surface and to prevent intestinal bacterial translocation after radiation exposure. Pasireotide did not protect the intestinal stem cells and the beneficial effect of Pasireotide could be reversed by pancreatic enzyme substitution. Therefore, Pasireotide does not seem to act as a cytoprotector, but to mitigate intestinal radiation injury by inhibiting pancreatic exocrine secretion. Until recent, knowledge on the effects of Pasireotide on the radiation-induced tumor response was scarce or non-existing at all. Pre-clinical studies have shown that Pasireotide may have a direct inhibiting effect on the growth of certain tumors such as neuroendocrine cancers. Moreover, it may reduce tumor growth by reducing the availability of growth factors such as IGF-1 and VEGF. However, no studies have been performed to assess the effect of Pasireotide on radiation-induced tumor growth delay. As Pasireotide can only be considered for clinical use if it does not hamper the anti-tumor effect of radiotherapy, we tested the effect of Pasireotide on tumor response to radiation in an animal model. The results of this recently performed study may enable a trial to test the potential beneficial effect on intestinal radiation injury in patients. The increasing number of dose escalation and hypofractionation prostate cancer trials is providing us excellent opportunities to learn more about ano-rectal,
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